Cardiovascular Agents

PreclinicalSmall molecule

UUMC Utrecht

Cardiovascular Agents is one of 3 small molecule programs targeting Polyp. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

PolypCompleted

PolypPreclinical

Completed

Competition

Competitive Landscape

3 competitors in Polyp

#DrugCompanyPhaseTrials

Alanine

UUniversity Hospital, Gentofte, Copenhagen

Phase 1

1 2

Cardiovascular Agents

UUMC Utrecht

Preclinical

1 3

Polypodium Leucotomos

HHenry Ford Health System

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Polyp1 trial

The Evening Versus Morning Polypill Utilization Study

Completed·UUMC Utrecht·N/A·NCT01506505·78 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Cardiovascular Agents. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Cardiovascular Agents compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Cardiovascular Agents. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — UMC Utrecht company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: UUMC Utrecht

Cardiovascular Agents

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Polyp1 trial

References

Drug Info

Quick Facts

Related News